Michael S Ritsner

Summary

Country: Israel

Publications

  1. doi request reprint Symptom severity scale of the DSM5 for schizophrenia, and other psychotic disorders: diagnostic validity and clinical feasibility
    Michael S Ritsner
    Department of Psychiatry, Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa and Sha ar Menashe Mental Health Center, Israel
    Psychiatry Res 208:1-8. 2013
  2. doi request reprint Factor structure in the Camberwell Assessment of Need-Patient Version: the correlations with dimensions of illness, personality and quality of life of schizophrenia patients
    Michael S Ritsner
    Department of Psychiatry, Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, and Sha ar Menashe Mental Health Center, Hadera, Israel
    Psychiatry Clin Neurosci 66:499-507. 2012
  3. doi request reprint Anhedonia is an important factor of health-related quality-of-life deficit in schizophrenia and schizoaffective disorder
    Michael S Ritsner
    Department of Psychiatry, Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
    J Nerv Ment Dis 199:845-53. 2011
  4. doi request reprint Ten-year quality of life outcomes among patients with schizophrenia and schizoaffective disorder II. Predictive value of psychosocial factors
    Michael S Ritsner
    Department of Psychiatry, Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
    Qual Life Res 21:1075-84. 2012
  5. doi request reprint Ten-year quality of life outcomes among patients with schizophrenia and schizoaffective disorders: I. Predictive value of disorder-related factors
    Michael S Ritsner
    Department of Psychiatry, Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
    Qual Life Res 21:837-47. 2012
  6. doi request reprint Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial
    Michael S Ritsner
    Department of Psychiatry, The Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
    J Clin Psychiatry 71:1351-62. 2010
  7. doi request reprint The clinical and therapeutic potentials of dehydroepiandrosterone and pregnenolone in schizophrenia
    M S Ritsner
    Department of Psychiatry, The Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
    Neuroscience 191:91-100. 2011
  8. doi request reprint Pregnenolone, dehydroepiandrosterone, and schizophrenia: alterations and clinical trials
    Michael S Ritsner
    Psychiatry Department, Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, and Sha ar Menashe Mental Health Center, Israel
    CNS Neurosci Ther 16:32-44. 2010
  9. doi request reprint L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study
    Michael S Ritsner
    Department of Psychiatry, The Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel
    J Clin Psychiatry 72:34-42. 2011
  10. doi request reprint Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial
    Anatoly Gibel
    Sha ar Menashe Mental Health Center, Hadera, Israel
    Clin Neuropharmacol 31:204-20. 2008

Detail Information

Publications20

  1. doi request reprint Symptom severity scale of the DSM5 for schizophrenia, and other psychotic disorders: diagnostic validity and clinical feasibility
    Michael S Ritsner
    Department of Psychiatry, Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa and Sha ar Menashe Mental Health Center, Israel
    Psychiatry Res 208:1-8. 2013
    ..The dimensional option for the diagnosis of schizophrenia and related disorders using SS-DSM5 is discussed...
  2. doi request reprint Factor structure in the Camberwell Assessment of Need-Patient Version: the correlations with dimensions of illness, personality and quality of life of schizophrenia patients
    Michael S Ritsner
    Department of Psychiatry, Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, and Sha ar Menashe Mental Health Center, Hadera, Israel
    Psychiatry Clin Neurosci 66:499-507. 2012
    ..To investigate the factor structure underlying the Camberwell Assessment of Need-Patient Version (CANSAS-P) items in schizophrenia and schizoaffective disorder...
  3. doi request reprint Anhedonia is an important factor of health-related quality-of-life deficit in schizophrenia and schizoaffective disorder
    Michael S Ritsner
    Department of Psychiatry, Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
    J Nerv Ment Dis 199:845-53. 2011
    ..Therefore, physical and social hedonic deficits significantly associated with poor HRQL independent of the adverse effects and psychopathological symptoms of SZ/SA. Physical anhedonia may be a predictor for quality-of-life deficit...
  4. doi request reprint Ten-year quality of life outcomes among patients with schizophrenia and schizoaffective disorder II. Predictive value of psychosocial factors
    Michael S Ritsner
    Department of Psychiatry, Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
    Qual Life Res 21:1075-84. 2012
    ..To identify psychosocial predictors of change in health-related quality of life among patients with schizophrenia (SZ) and schizoaffective (SA) disorders over a 10-year period...
  5. doi request reprint Ten-year quality of life outcomes among patients with schizophrenia and schizoaffective disorders: I. Predictive value of disorder-related factors
    Michael S Ritsner
    Department of Psychiatry, Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
    Qual Life Res 21:837-47. 2012
    ..To provide data on long-term health-related quality of life (HRQL) outcomes among patients with schizophrenia (SZ) and schizoaffective (SA) disorders and determine the predictive value of disorder-related factors...
  6. doi request reprint Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial
    Michael S Ritsner
    Department of Psychiatry, The Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
    J Clin Psychiatry 71:1351-62. 2010
    ..We investigated the influence of PREG and DHEA on psychotic symptoms and cognitive functioning as an add-on to ongoing antipsychotic treatment of patients with chronic schizophrenia or schizoaffective disorder...
  7. doi request reprint The clinical and therapeutic potentials of dehydroepiandrosterone and pregnenolone in schizophrenia
    M S Ritsner
    Department of Psychiatry, The Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
    Neuroscience 191:91-100. 2011
    ..The review concludes with a list of suggested topics for future research. This article is part of a Special Issue entitled: Neuroactive Steroids: Focus on Human Brain...
  8. doi request reprint Pregnenolone, dehydroepiandrosterone, and schizophrenia: alterations and clinical trials
    Michael S Ritsner
    Psychiatry Department, Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, and Sha ar Menashe Mental Health Center, Israel
    CNS Neurosci Ther 16:32-44. 2010
    ..This review also provides substantial information about clinical trials with DHEA and PREG augmentation with of antipsychotic agents in schizophrenia...
  9. doi request reprint L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study
    Michael S Ritsner
    Department of Psychiatry, The Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel
    J Clin Psychiatry 72:34-42. 2011
    ..This is a first study designed to evaluate the efficacy and tolerability of L-theanine augmentation of antipsychotic treatment of patients with chronic schizophrenia and schizoaffective disorder...
  10. doi request reprint Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial
    Anatoly Gibel
    Sha ar Menashe Mental Health Center, Hadera, Israel
    Clin Neuropharmacol 31:204-20. 2008
    ..Two questions were addressed in the present report: whether cognitive improvement would occur during 12-month ziprasidone treatment and whether the changes in cognitive functioning are dependent of changes in the illness-related variables...
  11. ncbi request reprint Predicting domain-specific insight of schizophrenia patients from symptomatology, multiple neurocognitive functions, and personality related traits
    Michael S Ritsner
    Sha ar Menashe Mental Health Center, Hadera, Israel
    Psychiatry Res 149:59-69. 2007
    ..The findings enable better understanding of the multifactorial nature of insight and highlight targets for more effective intervention and rehabilitation...
  12. doi request reprint Neurocognitive deficits in schizophrenia are associated with alterations in blood levels of neurosteroids: a multiple regression analysis of findings from a double-blind, randomized, placebo-controlled, crossover trial with DHEA
    Michael S Ritsner
    The Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Sha ar Menashe Mental Health Center, Hadera, Israel
    J Psychiatr Res 44:75-80. 2010
    ....
  13. ncbi request reprint Positive family history is associated with persistent elevated emotional distress in schizophrenia: evidence from a 16-month follow-up study
    Michael S Ritsner
    Sha ar Menashe Mental Health Center, Hadera, Israel Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
    Psychiatry Res 153:217-23. 2007
    ....
  14. ncbi request reprint Coping patterns as a valid presentation of the diversity of coping responses in schizophrenia patients
    Michael S Ritsner
    Sha ar Menashe Mental Health Center, Hadera, Israel
    Psychiatry Res 144:139-52. 2006
    ..Coping patterns may be considered an important source of knowledge for patients who struggle with the illness and for mental health professionals who work with schizophrenia patients...
  15. ncbi request reprint The long-term changes in coping strategies in schizophrenia: temporal coping types
    Michael S Ritsner
    Sha ar Menashe Mental Health Center, Hadera, Israel
    J Nerv Ment Dis 194:261-7. 2006
    ..The findings underscore the clinical relevance of temporal coping types and corroborate the appropriateness of focusing on aspects of coping behavior in treatment and rehabilitation of schizophrenia patients...
  16. ncbi request reprint Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial
    Michael S Ritsner
    Bruce Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
    J Clin Psychopharmacol 26:495-9. 2006
    ..In this study, the intention was to investigate the efficacy and safety of DHEA administration to ongoing antipsychotic medication in a multicenter, 12-week, double-blind, randomized, placebo-controlled, crossover trial...
  17. ncbi request reprint Predicting quality of life impairment in chronic schizophrenia from cognitive variables
    Michael S Ritsner
    The Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
    Qual Life Res 16:929-37. 2007
    ..The aim of this study was to see whether and how cognition deficit predicts quality of life impairments in schizophrenia patients...
  18. ncbi request reprint The effectiveness and predictors of response to antipsychotic agents to treat impaired quality of life in schizophrenia: A 12-month naturalistic follow-up study with implications for confounding factors, antidepressants, anxiolytics, and mood stabilizers
    Michael S Ritsner
    Sha ar Menashe Mental Health Center, Hadera, Israel
    Prog Neuropsychopharmacol Biol Psychiatry 30:1442-52. 2006
    ....
  19. ncbi request reprint Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial
    Yael Ratner
    Acute Department, Sha ar Menashe Mental Health Center, Mobile Post Hefer 38814, Hadera, Israel
    Prog Neuropsychopharmacol Biol Psychiatry 31:1401-9. 2007
    ....
  20. ncbi request reprint Life satisfaction and suicidal attempts among persons with schizophrenia
    Alexander M Ponizovsky
    Sha ar Menashe Mental Health Center, Hadera, Israel
    Compr Psychiatry 44:442-7. 2003
    ..Clinicians should include QOL in the evaluation of patients with schizophrenia that are suspected to be suicidal...